Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP580908.RA9qnNw2F5RSMHYH0fL3rGycHbRaVEvT3GIzVreGfF5HM130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP580908.RA9qnNw2F5RSMHYH0fL3rGycHbRaVEvT3GIzVreGfF5HM130_assertion type Assertion NP580908.RA9qnNw2F5RSMHYH0fL3rGycHbRaVEvT3GIzVreGfF5HM130_head.
- NP580908.RA9qnNw2F5RSMHYH0fL3rGycHbRaVEvT3GIzVreGfF5HM130_assertion description "[PBMC pretreatment with IL-2 allowed reaching 65 � 3% of Cetuximab-mediated ADCC against IIB-BR-G and 63 � 6.5% against IIB-BR-G MT.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP580908.RA9qnNw2F5RSMHYH0fL3rGycHbRaVEvT3GIzVreGfF5HM130_provenance.
- NP580908.RA9qnNw2F5RSMHYH0fL3rGycHbRaVEvT3GIzVreGfF5HM130_assertion evidence source_evidence_literature NP580908.RA9qnNw2F5RSMHYH0fL3rGycHbRaVEvT3GIzVreGfF5HM130_provenance.
- NP580908.RA9qnNw2F5RSMHYH0fL3rGycHbRaVEvT3GIzVreGfF5HM130_assertion SIO_000772 21308409 NP580908.RA9qnNw2F5RSMHYH0fL3rGycHbRaVEvT3GIzVreGfF5HM130_provenance.
- NP580908.RA9qnNw2F5RSMHYH0fL3rGycHbRaVEvT3GIzVreGfF5HM130_assertion wasDerivedFrom befree-20140225 NP580908.RA9qnNw2F5RSMHYH0fL3rGycHbRaVEvT3GIzVreGfF5HM130_provenance.
- NP580908.RA9qnNw2F5RSMHYH0fL3rGycHbRaVEvT3GIzVreGfF5HM130_assertion wasGeneratedBy ECO_0000203 NP580908.RA9qnNw2F5RSMHYH0fL3rGycHbRaVEvT3GIzVreGfF5HM130_provenance.